SKYE

Skye Bioscience, Inc. SKYE

SKYE
Skye Bioscience, Inc. ALGS
Aligos Therapeutics, Inc. XLO
Xilio Therapeutics, Inc. MRSN
Mersana Therapeutics, Inc. INMB
INmune Bio, Inc. XFOR
X4 Pharmaceuticals, Inc. KZR
Kezar Life Sciences, Inc. BRNS
Barinthus Biotherapeutics plc LVTX
LAVA Therapeutics N.V. PDSB
PDS Biotechnology Corporation

Net profit

EBITDA

P/E Ratio

Capitalization

Performance

Periode SKYE ALGS XLO MRSN INMB XFOR KZR BRNS LVTX PDSB
6M -53.71 % 37.35 % -5.59 % 218.03 % -71.47 % 37.08 % 39.82 % -13.04 % 32.82 % -45.91 %
YTD -64.92 % -73.96 % -39.25 % -16.86 % -63.08 % -83.78 % -3.81 % -41.02 % 68.93 % -49.35 %
1Y -65.04 % -72.96 % -30.70 % -33.10 % -58.82 % -79.91 % -3.07 % -28.29 % 75.95 % -49.93 %
3Y -69.23 % -58.93 % -68.60 % -79.54 % -75.44 % -82.32 % -99.04 % -66.14 % -53.97 % -90.35 %
5Y -91.11 % -98.45 % -95.94 % -95.65 % -83.04 % -98.10 % -98.80 % -94.81 % -87.83 % -60.70 %
10Y -99.43 % -97.21 % -95.94 % -91.69 % -77.22 % -99.86 % -99.64 % -94.81 % -87.83 % -99.64 %
From the beginning -99.96 % -97.21 % -95.94 % -91.69 % -77.22 % -99.86 % -99.64 % -94.81 % -87.83 % -99.60 %

Dividend